Erratum: Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the fourth international workshop (Journal of Clinical Endocrinology & Metabolism (2014) 99 (3570-3579) DOI: 10.1210/jc.2014-1414);Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the fourth international workshop

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3570-3579

  Eastell, Richard ^a   Brandi, Maria Luisa ^b   Costa, Aline G ^c,d   D'Amour, Pierre ^e   Shoback, Dolores M ^f   Thakker, Rajesh V ^g  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Columbia University ^*  (United States)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF MONTREAL   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D;

AP2S1 GENE; CASR GENE; CLINICAL PRACTICE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; GENE; GENE MUTATION; GENETIC SCREENING; GNA11 GENE; HORMONE DETERMINATION; HUMAN; HYPERCALCEMIA; MULTIPLE ENDOCRINE NEOPLASIA; MUTATIONAL ANALYSIS; PARATHYROID HORMONE ASSAY; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; ASYMPTOMATIC DISEASE; BLOOD; EDUCATION; ENDOCRINOLOGY; EVIDENCE BASED MEDICINE; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINE; STANDARDS;

ASYMPTOMATIC DISEASES; EDUCATION; ENDOCRINOLOGY; EVIDENCE-BASED MEDICINE; HUMANS; HYPERPARATHYROIDISM, PRIMARY; PRACTICE GUIDELINES AS TOPIC;

EID: 84907652050     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1771     Document Type: Erratum

References (60)

1. Eastell R, Arnold A, Brandi ML, et al. Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:340-350.
2. Caron P, Simonds WF, Maiza JC, et al. Nontruncated amino-terminal parathyroid hormone overproduction in two patients with parathyroid carcinoma: a possible link to HRPT2 gene inactivation. Clin Endocrinol (Oxf). 2011;74:694-698.
3. Gao P, Scheibel S, D'Amour P, et al. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res. 2001;16:605-614.
4. Silverberg SJ, Gao P, Brown I, Lo Gerfo P, Cantor TL, Bilezikian JP. Clinical utility of an immunoradiometric assay for parathyroid hormone (1-84) in primary hyperparathyroidism. J Clin Endocrinol Metab. 2003;88:4725-4730.
5. Carnevale V, Dionisi S, Nofroni I, et al. Potential clinical utility of a new IRMA for parathyroid hormone in postmenopausal patients with primary hyperparathyroidism. Clin Chem. 2004;50:626-631.
6. Boudou P, Ibrahim F, Cormier C, Chabas A, Sarfati E, Souberbielle JC. Third- or second-generation parathyroid hormone assays: a remaining debate in the diagnosis of primary hyperparathyroidism. J Clin Endocrinol Metab. 2005;90:6370-6372.
7. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.
8. Rosen CJ, Abrams SA, Aloia JF, et al. IOM committee members respondto Endocrine Society vitamin D guideline. J Clin Endocrinol Metab. 2012;97:1146-1152.
9. Björkman M, Sorva A, Tilvis R. Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr. 2009;48:160-166.
10. Kawahara M, Iwasaki Y, Sakaguchi K, et al. Predominant role of 25OHD in the negative regulation of PTH expression: clinical relevance for hypovitaminosis D. Life Sci. 2008;82:677-683.
11. Fillée C, Keller T, Mourad M, Brinkmann T, Ketelslegers JM. Impact of vitamin D-related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium/PTH reference regions. Clin Endocrinol (Oxf). 2012;76:785-789.
12. Wallace LB, Parikh RT, Ross LV, et al. The phenotype of primary hyperparathyroidism withnormal parathyroid hormone levels: how low can parathyroid hormone go? Surgery. 2011;150:1102-1112.
13. Amin AL, Wang TS, Wade TJ, Yen TW. Normal PTH levels in primary hyperparathyroidism: still the same disease? Ann Surg Oncol. 2011;18:3437-3442.
14. Björkman M, Sorva A, Risteli J, Tilvis R. Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients. Age Ageing. 2008;37:25-31.
15. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16:33-39.
16. Nordenström E, Katzman P, Bergenfelz A. Biochemical diagnosis of primary hyperparathyroidism: analysis of the sensitivity of total and ionized calcium in combination with PTH. Clin Biochem. 2011;44:849-852.
17. Ong GS, Walsh JP, Stuckey BG, et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97:3138-3145.
18. Mallette LE, Khouri K, Zengotita H, Hollis BW, Malini S. Lithium treatment increases intact and midregion parathyroid hormone and parathyroid volume. J Clin Endocrinol Metab. 1989;68:654-660.
19. Mallette LE, Eichhorn E. Effects of lithium carbonate on human calcium metabolism. Arch Intern Med. 1986;146:770-776.
20. Makras P, Polyzos SA, Papatheodorou A, Kokkoris P, Chatzifotiadis D, Anastasilakis AD. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis. Clin Endocrinol (Oxf). 2013;79:499-503.
21. Ghervan C, Silaghi A, Nemes C. Parathyroid incidentaloma detected during thyroid sonography - prevalence and significance beyond images. Med Ultrason. 2012;14:187-191.
22. Kwak JY, Kim EK, Moon HJ, et al. Parathyroid incidentalomas detected on routine ultrasound-directed fine-needle aspiration biopsy in patients referred for thyroid nodules and the role of parathyroid hormone analysis in the samples. Thyroid. 2009;19:743-748.
23. Koumakis E, Souberbielle JC, Sarfati E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98:3213-3220.
24. Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L. Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab. 2013;98:87-96.
25. Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001-3005.
26. Cusano NE, Maalouf NM, Wang PY, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab. 2013;98:2734-2741.
27. 3 deficiency is associated with lateonset hypocalcemia after minimally invasive parathyroidectomy in a vitamin D borderline area. World J Surg. 2010;34:1350-1355.
28. Saliba W, Lavi I, Rennert HS, Rennert G. Vitamin D status in primary hyperparathyroidism. Eur J Intern Med. 2012;23:88-92.
29. Bollerslev J, Marcocci C, Sosa M, Nordenström J, Bouillon R, Mosekilde L. Current evidence for recommendation of surgery, medical treatment and vitamin D repletion in mild primary hyperparathyroidism. Eur J Endocrinol. 2011;165:851-864.
30. Boudou P, Ibrahim F, Cormier C, Sarfati E, Souberbielle JC. Potential utility of high preoperative levels of serum type I collagen markers in postmenopausal women with primary hyperparathyroidism with respect to their short-term variations after parathyroidectomy. J Bone Miner Metab. 2009;27:240-246.
31. Priya G, Jyotsna VP, Gupta N, et al. Clinical and laboratory profile of primary hyperparathyroidism in India. Postgrad Med J. 2008;84:34-39.
32. Moosgaard B, Christensen SE, Vestergaard P, Heickendorff L, Christiansen P, Mosekilde L. Vitamin D metabolites and skeletal consequences in primary hyperparathyroidism. Clin Endocrinol (Oxf). 2008;68:707-715.
33. Amstrup AK, Rejnmark L, Vestergaard P, et al. Vitamin D status, physical performance and body mass in patients surgically cured for primary hyperparathyroidism compared with healthy controls - a cross-sectional study. Clin Endocrinol (Oxf). 2011;74:130-136.
34. Farahnak P, Lärfars G, Sten-Linder M, Nilsson IL. Mild primary hyperparathyroidism: vitamin D deficiency and cardiovascular risk markers. J Clin Endocrinol Metab. 2011;96:2112-2118.
35. Kandil E, Tufaro AP, Carson KA, et al. Correlation of plasma 25-hydroxyvitamin D levels with severity of primary hyperparathyroidism and likelihood of parathyroid adenoma localization on sestamibi scan. Arch Otolaryngol Head Neck Surg. 2008;134:1071-1075.
36. Grubbs EG, Rafeeq S, Jimenez C, et al. Preoperative vitamin D replacement therapy inprimary hyperparathyroidism: safe and beneficial? Surgery. 2008;144:852-858; discussion 858-859.
37. Stein EM, Dempster DW, Udesky J, et al. Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. Bone. 2011;48:557-561.
38. Walker MD, Fleischer JB, Di Tullio MR, et al. Cardiac structure and diastolic function in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2010;95:2172-2179.
39. Tucci JR. Vitamin D therapy in patients with primary hyperparathyroidism and hypovitaminosis D. Eur J Endocrinol. 2009;161:189-193.
40. Isidro ML, Ruano B. Biochemical effects of calcifediol supplementation in mild, asymptomatic, hyperparathyroidism with concomitant vitamin D deficiency. Endocrine. 2009;36:305-310.
41. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97:2990-3011.
42. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19:565-612.
43. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386:2-15.
44. Sharretts JM, Simonds WF. Clinical and molecular genetics of parathyroid neoplasms. Best Pract Res Clin Endocrinol Metab. 2010;24:491-502.
45. Westin G, Björklund P, Akerström G. Molecular genetics of parathyroid disease. World J Surg. 2009;33:2224-2233.
46. Hannan FM, Nesbit MA, Christie PT, et al. Familial isolated primary hyperparathyroidism caused by mutations of the MEN1 gene. Nat Clin Pract Endocrinol Metab. 2008;4:53-58.
47. Hannan FM, Nesbit MA, Christie PT, et al. A homozygous inactivating calcium-sensing receptor mutation, Pro339Thr, is associated with isolated primary hyperparathyroidism: correlation between location of mutations and severity of hypercalcaemia. Clin Endocrinol (Oxf). 2010;73:715-722.
48. Vierimaa O, Villablanca A, Alimov A, et al. Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition. J Endocrinol Invest. 2009;32:512-518.
49. Frank-Raue K, Leidig-Bruckner G, Haag C, et al. Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2011;75:50-55.
50. Hannan FM, Nesbit MA, Zhang C, et al. Identification of 70 calcium-sensing receptor mutations in hyper- and hypo-calcaemic patients: evidence for clustering of extracellular domain mutations at calcium-binding sites. Hum Mol Genet. 2012;21:2768-2778.
51. Eldeiry LS, Ruan DT, Brown EM, Gaglia JL, Garber JR. Primary hyperparathyroidism and familial hypocalciuric hypercalcemia: relationships and clinical implications. Endocr Pract. 2012;18:412-417.
52. Christensen SE, Nissen PH, Vestergaard P, Heickendorff L, Brixen K, Mosekilde L. Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin Endocrinol (Oxf). 2008;69:713-720.
53. Nesbit MA, Hannan FM, Howles SA, et al. Mutations affecting G-protein subunit a11 in hypercalcemia and hypocalcemia. NEngl J Med 2013;368:2476-2486.
54. Nesbit MA, Hannan FM, Howles SA, et al. Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat Genet. 2013;45:93-97.
55. Starker LF, Akerström T, Long WD, et al. Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 2012;3:44-51.
56. Costa-Guda J, Soong CP, Parekh VI, Agarwal SK, Arnold A. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 2013;4:301-307.
57. Jayasena CN, Mahmud M, Palazzo F, Donaldson M, Meeran K, Dhillo WS. Utility of the urine calcium-to-creatinine ratio to diagnose primary hyperparathyroidism in asymptomatic hypercalcaemic patients with vitamin D deficiency. Ann Clin Biochem. 2011;48:126-129.
58. Taha W, Singh N, Flack JM, Abou-Samra AB. Low urine calcium excretion in African American patients with primary hyperparathyroidism. Endocr Pract. 2011;17:867-872.
59. Cromer MK, Starker LF, Choi M, et al. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab. 2012;97:E1774-E1781.
60. Newey PJ, Nesbit MA, Rimmer AJ, et al. Whole-exome sequencing studies of nonhereditary (sporadic) parathyroid adenomas. J Clin Endocrinol Metab. 2012;97:E1995-E2005.